MEDINCELL SA (MEDCL.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:MEDCL - FR0004065605 - Common Stock
MEDCL.PA Key Statistics, Chart & Performance
The current stock price of MEDCL.PA is 28.16 EUR. In the past month the price decreased by -26.78%. In the past year, price increased by 55.41%.
MEDCL.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1SAN.MI | SANOFI | 11.36 | 209.67B | ||
| SAN.PA | SANOFI | 11.28 | 208.31B | ||
| SNW.DE | SANOFI | 11.28 | 208.31B | ||
| MRK.DE | MERCK KGAA | 13.6 | 50.43B | ||
| UCB.BR | UCB SA | 37.46 | 46.78B | ||
| UNC.DE | UCB SA | 37.17 | 46.41B | ||
| 1BAYN.MI | BAYER AG-REG | 5.75 | 30.17B | ||
| BAYN.DE | BAYER AG-REG | 5.71 | 29.95B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 25.84 | 10.64B | ||
| IPN.PA | IPSEN | 12.1 | 10.42B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 100.96 | 9.35B | ||
| 1JAZZ.MI | JAZZ PHARMACEUTICALS PLC | 18.41 | 7.90B |
Related stock screener links
About MEDCL.PA
Company Profile
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 140 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
Company Info
MEDINCELL SA
3 Rue des Freres Lumiere
Jacou OCCITANIE FR
Employees: 131
Phone: 33467021367
MEDINCELL SA / MEDCL.PA FAQ
What does MEDINCELL SA do?
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 140 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
What is the stock price of MEDINCELL SA today?
The current stock price of MEDCL.PA is 28.16 EUR. The price increased by 0.36% in the last trading session.
Does MEDCL stock pay dividends?
MEDCL.PA does not pay a dividend.
How is the ChartMill rating for MEDINCELL SA?
MEDCL.PA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is MEDCL.PA stock listed?
MEDCL.PA stock is listed on the Euronext Paris exchange.
Can you provide the PE ratio for MEDCL stock?
MEDINCELL SA (MEDCL.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.63).
What is the market capitalization of MEDCL stock?
MEDINCELL SA (MEDCL.PA) has a market capitalization of 932.94M EUR. This makes MEDCL.PA a Small Cap stock.
MEDCL.PA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to MEDCL.PA. When comparing the yearly performance of all stocks, MEDCL.PA is one of the better performing stocks in the market, outperforming 96.7% of all stocks.
MEDCL.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MEDCL.PA. The financial health of MEDCL.PA is average, but there are quite some concerns on its profitability.
MEDCL.PA Financial Highlights
Over the last trailing twelve months MEDCL.PA reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 28.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.38% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MEDCL.PA Forecast & Estimates
17 analysts have analysed MEDCL.PA and the average price target is 36.04 EUR. This implies a price increase of 28% is expected in the next year compared to the current price of 28.16.
For the next year, analysts expect an EPS growth of 78.94% and a revenue growth 22.24% for MEDCL.PA